Clinical Trial Update: Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy [Phase 4]

View source ↗

Summary

A Phase 4 trial assessed the safety and efficacy of omalizumab given prior to immunotherapy in asthma; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab) (omalizumab)

Snippet

Sponsor: University of Mississippi Medical Center | Conditions: Asthma | Phase 4 | Status: COMPLETED